Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in moderate-to-severe asthma
NCT05421598Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in asthma (4 arms), sponsored by Sanofi. Primary endpoint: Annualized Rate of Severe Asthma Exacerbation Events at 48 weeks. Started Jun 2022; status: completed.
02
Drugs
amlitelimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05421598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421598.